Development asset linked to Arcus Biosciences in public FDA and regional records.
pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS
Arcus Biosciences
Arcus Biosciences drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3928 Point Eden Way, Hayward, California 94545, US HQ
2015 Founded
655 Employees
Public company Type
RCUS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3928 Point Eden Way, Hayward, California 94545, US
- Founded
- 2015
- Employees
- 655
- Programs
- 53
- Drugs
- 25
- Patents
- 30
Arcus Biosciences pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Arcus Biosciences drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Arcus Biosciences's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Mechanism: Releases NO, antimicrobial.
- Mechanism
- Releases NO, antimicrobial
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
US regulatory status: approved.
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
regorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.
- Target
- Discoidin domain-containing receptor 2
- Mechanism
- Fibroblast growth factor receptor 2 inhibitor
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
Development asset linked to Arcus Biosciences in public FDA and regional records.
-
tobramycin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: 70S ribosome.
- Target
- 70S ribosome
- Mechanism
- 70S ribosome inhibitor